Tag Archives: Orphan Drug Designations

NORD Summit 2016 Highlights

By Kimberley Cummings, Ph.D., RAC (US), Vice President, Scientific & Regulatory Strategy and Operations Cato Research   The National Organization for Rare Disorders (NORD) held their annual Rare Diseases and Orphan Products Breakthrough Summit in Arlington, VA on October 17th … Continue reading

Posted in Cato Research, FDA, Medical Research, Rare Diseases | Tagged , , , | Comments Off on NORD Summit 2016 Highlights

Health Canada Orphan Drug Policy – A Long Overdue Need

Canada is one of the only first world countries without an orphan drug policy. The United States, European Union, Australia, Singapore, and Japan recognized a long time ago the importance of having established policies around the development of orphan drugs. … Continue reading

Posted in Health Canada, Regulatory Strategy | Tagged , , , , , , , , | Comments Off on Health Canada Orphan Drug Policy – A Long Overdue Need

Meningitis Tragedy Leads to Calls for Increased FDA Oversight

On 25 September 2012, three lots of steroid injections intended to treat pain were recalled by the pharmaceutical compounding company New England Compounding Center (NECC) in Framingham, MA, because of fungal contamination.  By Thursday, 11 October 2012, 12 people had … Continue reading

Posted in FDA, Industry News | Tagged , , , , , , , | Comments Off on Meningitis Tragedy Leads to Calls for Increased FDA Oversight

FDASIA, Part 4: Drug Supply Chain, Drug Shortages, and Other Provisions

On 09 July 2012, the Food and Drug Administration Safety and Innovation Act (FDASIA, otherwise known as PDUFA V) was signed into law.  In a 4-part weekly series, we are covering the major changes in FDASIA as follows: Part 1: … Continue reading

Posted in Clinical Trials, eCTD, FDA, Industry News, Regulatory Strategy | Tagged , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , | 1 Comment

FDASIA, Part 3: Generating Antibiotic Incentives Now (GAIN) and Drug Approval and Patient Access Changes

On 09 July 2012, the Food and Drug Administration Safety and Innovation Act (FDASIA, otherwise known as PDUFA V) was signed into law.  In a 4-part weekly series, we are covering the major changes in FDASIA as follows: Part 1: … Continue reading

Posted in FDA, Industry News, Regulatory Strategy | Tagged , , , , , , , , , , , , , , , , , , , | 4 Comments